East Hills, NY (March 10, 2005) - - Pall Corporation (NYSE: PLL) today announced that it has signed a new multi-year contract for leukocyte (white blood cell) reduction filters with Gambro BCT, Inc. Pall will be the sole source, global provider of leukoreduction filters for red cells, plasma and platelets for Gambro BCT's automated blood collection and whole blood processing systems.
The new agreement through 2010 is an expansion of a five-year long relationship between the two companies. Pall currently provides red cell leukoreduction filters for Gambro BCT's Trima® Automated Blood Collection System. The Trima system enables blood centers to collect multiple component combinations of leukoreduced, ready-to-store red cells - including double red cells - platelets and plasma, from a single donor, in a single donation.
Gambro BCT is developing automated processing technologies for blood centers to separate whole blood into leukoreduced components in a single step. Blood centers generally carry out these processes manually with time-consuming, labor-intensive steps. Automation of whole blood processing will deliver high quality, consistent blood components, and Pall's leukoreduction filters will be a critical element of this new technology.
"Our relationship with Pall is mutually beneficial for all of our stakeholders, including blood centers and the transfusion patients they serve," says David Perez, President of Gambro BCT. "Pall's proven track record, deep product line and innovation in developing the most advanced leukocyte reduction technologies is an ideal fit with our automated blood processing and collection systems today and for the future."
Allan Ross, President of Pall Medical, says, "We are pleased that Gambro BCT recognizes the quality of our products by selecting Pall as its exclusive supplier of leukoreduction technology. We are delivering world-class leukoreduction filters to a worldwide leader in automated blood collection and processing."
Pall Medical is the global leader in leukocyte reduction technologies. The Company is currently finalizing development of its latest advance in leukocyte reduction. The Pall Leukotrap® Affinity Prion Reduction Filter reduces both leukocytes and prions from blood in a single step. Prions are associated with several fatal neurodegenerative diseases including variant Creutzfeldt-Jakob Disease (vCJD), the human form of ?mad cow disease?. Pall expects to introduce the new filter in Europe this spring.
Gambro BCT, Inc. headquartered in Lakewood, Colorado, is a world leader in blood bank technologies, automated blood collections and processing, pathogen reduction techniques and valued added blood and cell-based therapeutic services. Gambro BCT operates production facilities in the US and the UK, and has sales in more than 90 countries. It is a wholly owned subsidiary of Gambro AB, a global medical technology and healthcare company.
About Pall Corporation Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2004 were $1.8 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at http://www.pall.com.
This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the Web at www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.
Management uses certain non-GAAP measurements to assess Pall's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing Pall's financial position and results of operations. Pall has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of on-going operations.